A Phase 3 Randomized, Placebo-Controlled, CLinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia.
Latest Information Update: 11 Aug 2023
Price :
$35 *
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms PEARL-1
- Sponsors Sumitomo Pharma America
- 09 Nov 2021 Results of pooled analysis evaluating novelty of a safety profile of a drug in a new class (in clinical trials), against that of those already on the market (using pharmacovigilance data) published in the Clinical Drug Investigation
- 20 Sep 2016 Results of pooled, post hoc analysis of this and other four trials presented at the 29th Annual Congress of the European College of Neuropsychopharmacology
- 20 Sep 2016 Results of pooled, post hoc analysis of this trial and other 4 trials were presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.